{"id":3355,"date":"2011-02-28T10:36:50","date_gmt":"2011-02-28T15:36:50","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=3355"},"modified":"2011-02-28T10:36:50","modified_gmt":"2011-02-28T15:36:50","slug":"biotech-licenses-technology-for-colorectal-cancer-blood-test","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=3355","title":{"rendered":"Biotech Licenses Technology for Colorectal Cancer Blood Test"},"content":{"rendered":"<figure id=\"attachment_3357\" aria-describedby=\"caption-attachment-3357\" style=\"width: 267px\" class=\"wp-caption alignright\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/DNAstrand_NSF.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-3357\" title=\"DNAstrand_NSF\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/DNAstrand_NSF.jpg\" alt=\"DNA strand (NSF)\" width=\"267\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/DNAstrand_NSF.jpg 267w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/DNAstrand_NSF-150x112.jpg 150w\" sizes=\"auto, (max-width: 267px) 100vw, 267px\" \/><\/a><figcaption id=\"caption-attachment-3357\" class=\"wp-caption-text\">(James. J. Caras, NSF)<\/figcaption><\/figure>\n<p><a href=\"http:\/\/www.epigenomics.com\/en\/Newsroom\/\">Epigenomics AG<\/a> in Berlin, Germany says it has an agreement for <a href=\"http:\/\/www.qiagen.com\/\">QIAGEN NV<\/a> in the Netherlands to further develop Epigenomics&#8217;s research into a blood test for colorectal cancer. QIAGEN also has an option under the agreement to take the blood test to market.<\/p>\n<p>The technology is based on Epigenomics&#8217;s research into genomics and DNA indicators of cancer. The company says that numerous studies have shown a correlation between the Septin9 biomarker in blood plasma and the presence of colorectal cancer, and thus can be used to help detect this common cancer. A blood test that is more convenient for the patients than stool tests or a colonoscopy could encourage more people to be screened.<\/p>\n<p>QIAGEN is a developer of technologies to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. The company also makes assay technologies to make such isolated bio-molecules visible.<\/p>\n<p>Under the agreement, Epigenomics will receive an initial payment from QIAGEN and reimbursement for R&amp;D support and clinical specimens provided during the R&amp;D phase. If QIAGEN exercises the option to commercialize the test, Epigenomics would receive a further license payment. Once QIAGEN takes a colorectal cancer blood test to market based on Epigenomics&#8217; biomarkers and technology, Epigenomics would be entitled to royalties on QIAGEN&#8217;s net sales and milestone payments.<\/p>\n<p>Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=2378\">Genetic Signature Validated for Early-Stage Colon Cancer<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Epigenomics AG in Berlin, Germany says it has an agreement for QIAGEN NV in the Netherlands to further develop Epigenomics&#8217;s research into a blood test for colorectal cancer. QIAGEN also has an option under the agreement to take the blood test to market. The technology is based on Epigenomics&#8217;s research into genomics and DNA indicators [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[31,21,51,45,55,84,64,77],"class_list":["post-3355","post","type-post","status-publish","format-standard","hentry","category-i-p","tag-biomedical","tag-biotech","tag-cancer","tag-europe","tag-genomics","tag-licensing","tag-life-sciences","tag-medical-device"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3355"}],"version-history":[{"count":2,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3355\/revisions"}],"predecessor-version":[{"id":3358,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3355\/revisions\/3358"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}